bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Production of a Highly Immunogenic Antigen from
SARS-CoV-2 by Covalent Coupling of the Receptor
Binding Domain of Spike Protein to a Multimeric Carrier
Argentinian AntiCovid Consortium*: Paula M. Berguer1,2,*, Mat√≠as Blaustein1,3,*, Luis M.
Bredeston4,5,*, Patricio O. Craig6,7,*, Cecilia D‚ÄôAlessio1,3,*, Fernanda Elias8,*, Paola C. Farr√©9,
Natalia B. Fern√°ndez1,3,*, Hern√°n G. Gentili3,*, Yamila B. G√°ndola3,*, Javier Gasulla3,10,*,
Gustavo

E.

Gudesblat1,3,*, Mar√≠a

G.

Herrera1,3,*,

Lorena

I.

Iba√±ez1,11,*,

Tommy

Idrovo-Hidalgo3,*, Alejandro D. Nadra1,3,*, Diego G. Noseda12,*, Carlos H. Pav√°n1,13,*, Mar√≠a F.
Pavan1,11,* Mar√≠a F. Pignataro3,*, Ernesto A. Roman4,5,*, Lucas A. M. Ruberto14,15,16,*, Natalia
Rubinstein1,3,* Mar√≠a V. Sanchez17,*, Javier Santos1,3,6,*, Diana E. Wetzler6,7,*, Alicia M.
Zelada18,19,*

*Argentinian AntiCovid Consortium: All authors (listed in alphabetical order) contributed
equally to this work. anticovid.arg@gmail.com
1

Consejo Nacional de Investigaciones Cient√≠ficas y T√©cnicas. Godoy Cruz 2290 C1425FQB,

Buenos Aires, Argentina.
2

Fundaci√≥n Instituto Leloir, IIBBA, Consejo Nacional de Investigaciones Cient√≠ficas y

T√©cnicas (CONICET), Buenos Aires, Argentina.
3

Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Instituto de

Biociencias, Biotecnolog√≠a y Biolog√≠a Traslacional (iB3). Intendente G√ºiraldes 2160, Ciudad
Universitaria, C1428EGA, Buenos Aires, Argentina.
4

Instituto de Qu√≠mica y Fisicoqu√≠mica Biol√≥gicas. Facultad de Farmacia y Bioqu√¨mica,

Universidad de Buenos Aires, Jun√≠n 956, 1113AAD, Buenos Aires, Argentina.

1

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

5

Departamento de Qu√≠mica Biol√≥gica , Facultad de Farmacia y Bioqu√≠mica, Universidad de

Buenos Aires, Buenos Aires, Argentina.
6

Departamento de Qu√≠mica Biol√≥gica. Facultad de Ciencias Exactas y Naturales. Universidad

de Buenos Aires. Intendente G√ºiraldes 2160, Ciudad Universitaria, C1428EGA, Buenos
Aires, Argentina.
7

Instituto de Qu√≠mica Biol√≥gica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN-

CONICET). Buenos Aires, Argentina.
8

Instituto de Ciencia y Tecnolog√≠a Dr. C√©sar Milstein (Consejo Nacional de Investigaciones

Cient√≠ficas y T√©cnicas-Fundaci√≥n Pablo Cassar√°), Saladillo 2468, C1440FFX Buenos Aires,
Argentina.
9

Laboratorio Pablo Cassara S.R.L.

10

Centro de Investigaciones del Medioambiente (UNLP-CONICET), La Plata, Buenos Aires,

Argentina
11

Departamento de Qu√≠mica Inorg√°nica, Anal√≠tica y Qu√≠mica F√≠sica, Facultad de Ciencias

Exactas y Naturales, Universidad de Buenos Aires. Instituto de Qu√≠mica F√≠sica de los
Materiales, Medio Ambiente y Energ√≠a (INQUIMAE CONICET), C1428EGA, Buenos Aires,
Argentina
12

Universidad

Nacional

de

San

Mart√≠n-CONICET,

Instituto

de

Investigaciones

Biotecnol√≥gicas (IIBio), San Mart√≠n, Buenos Aires, Argentina
13

Instituto de Qu√≠mica y Fisicoqu√≠mica Biol√≥gicas, LANAIS PROEM, Facultad de Farmacia

y Bioqu√¨mica, Universidad de Buenos Aires, Jun√≠n 956, 1113AAD, Buenos Aires, Argentina.
14

Departamento de Microbiolog√≠a, Inmunolog√≠a, Biotecnolog√≠a y Gen√©tica, Facultad de

Farmacia y Bioqu√≠mica, Universidad de Buenos Aires, Buenos Aires, Argentina.

2

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

15

CONICET-Universidad de Buenos Aires, Facultad de Farmacia y Bioqu√≠mica, Instituto de

Nanobiotecnolog√≠a (NANOBIOTEC), Buenos Aires, Argentina.
16

Instituto Ant√°rtico Argentino, Ministerio de Relaciones Exteriores y Culto, Buenos Aires,

Argentina.
17

Instituto de Medicina y Biolog√≠a Experimental de Cuyo (IMBECU).Centro Cient√≠fico

Tecnol√≥gico de Mendoza ( CCT-Mendoza), CONICET, Universidad Nacional de Cuyo,
(5500), Mendoza, Argentina.
18

Departamento de Fisiolog√≠a y Biolog√≠a Molecular y Celular. Universidad de Buenos Aires

Facultad

de

Ciencias

Exactas

y

Naturales-

Universidad

de

Buenos

Aires,

Argentina.Intendente G√ºiraldes 2160, Ciudad Universitaria, C1428EGA, Buenos Aires,
Argentina.
19

Instituto de Biodiversidad y Biolog√≠a Experimental y Aplicada (IBBEA-UBA-CONICET).

Facultad de Ciencias Exactas y Naturales. Buenos Aires, Argentina.

Abbreviations:
ACE2, angiotensin-converting enzyme 2; BLS, lumazine synthase from Brucella abortus;
CD, circular dichroism; CoV, Coronavirus; EDTA, Ethylenediaminetetraacetic acid; ELISA,
enzyme-linked immunosorbent assay; ESI-MS, electrospray ionization mass spectrometry;
GFP, green fluorescent protein; HM, high multiplicity; HPLC, high-performance liquid
chromatography;

IPTG,

Isopropyl

Œ≤-D-1-thiogalactopyranoside,

Isopropyl

Œ≤-D-thiogalactoside; LM, low multiplicity; LPS, lipopolysaccharide; LS, lumazine synthase;
NTA-Ni2+, nickel-charged nitrilotriacetic acid affinity resin; PBS, phosphate-buffered saline;
PDB, Protein Data Bank; PEI, Polyethylenimine; RBD, receptor binding domain; RBD-BLS,
the multimeric particle constituted by RBD covalently coupled to the BLS decamer;
RBD-TMR, RBD covalently coupled to tetramethylrhodamine; SARS-CoV-1, severe acute
respiratory syndrome coronavirus 1; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; SDS-PAGE, polyacrylamide gel electrophoresis; SEC, size exclusion

3

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

chromatography; TEV, Tobacco Etch Virus protease; TMR, tetramethylrhodamine, TFA,
trifluoroacetic acid; SDS-PAGE, SDS polyacrylamide gel electrophoresis.

Abstract
Since the discovery of SARS-CoV-2, several antigens have been proposed to be part of
COVID-19 vaccines. The receptor binding domain (RBD) of Spike protein is one of the promising
candidates to develop effective vaccines since it can induce potent neutralizing antibodies. We
previously reported the production of RBD in Pichia pastoris and showed it is structurally
identical to the protein produced in mammalian HEK-293T cells. In this work we designed an
RBD multimer construct with the purpose of increasing RBD immunogenicity. We produced
multimeric particles by a transpeptidation reaction between the RBD expressed in P. pastoris and
Lumazine Synthase from Brucella abortus (BLS), which is a highly immunogenic and very
stable decameric protein of 170 kDa. We vaccinated mice with two doses 30 days apart, and then
we measured humoral immune response. When the number of RBD copies coupled to BLS was
high (6-7 RBD molecules per BLS decamer, in average), the immune response was significantly
better than that elicited by RBD alone or even by RBD-BLS comprising low number of RBD
copies (1-2 RBD molecules per BLS decamer). Remarkably, the construct with high number of
RBD copies induced high IgG titers with high neutralizing capacity. Furthermore, a superior
immune response was observed when Al(OH)3 adjuvant was added to this formulation,
exhibiting a higher titer of neutralizing antibodies. Altogether our results suggest that RBD
covalent coupled to BLS forming a multimer-particle shows an advantageous architecture to the
antigen-presentation to the immune system which enhances immune responses. This new antigen
should be considered a potent candidate for a protein-based vaccine.

4

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Introduction
The coronavirus SARS-CoV-2, which was detected about one year ago in Wuhan, Republic
of China in December 2019, has produced over 3.0 million deaths by April, 2021
(https://ourworldindata.org/covid-deaths). Since the discovery of the new strain, several vaccines
have been developed (https://covid19.trackvaccines.org/vaccines/), based on inactivated viruses,
DNA, RNA and/or proteins1‚Äì3. Furthermore, multivalent antigens that mimic antigen
presentation by viral particles have been shown to induce a stronger immune response than
monomeric antigens4, thus allowing immunization with lower doses of antigen, as well as the
combination of different antigen variants. This approach would be critical in the specific case of
new circulating SARS-CoV-2 lineages that have unfortunately emerged around the world5.
The receptor binding domain (RBD) of SARS-CoV-2 Spike protein is responsible for the
interaction of the virus with the receptor Angiotensin-Converting Enzyme 2 (ACE2)6, which
allows the penetration of the virus into the cells. Therefore, RBD constitutes a suitable target to
develop diagnostic and therapeutic tools, as well as vaccines. It has been found that several
neutralizing antibodies produced upon SARS-CoV-2 infection are directed towards RBD7,8. The
structure of the complex formed by SARS-CoV-2 RBD and human ACE2 was recently
determined9. Unlike SARS-CoV-1, several residue changes in SARS-CoV-2 RBD stabilize two
virus-binding hotspots at the RBD/ACE2 interface increasing the affinity for ACE2 9.
SARS-CoV-2 Spike‚Äôs RBD is a challenging protein to produce in heterologous systems
because it has nine cysteine residues (eight of which form disulfide bonds), a complex topology
and two N-glycosylation sites10,11. For these reasons, RBD is often expressed in mammalian
cells9,12. Nevertheless, our AntiCovid consortium was able to produce RBD at high yields in
Pichia pastoris. Its immunogenicity, stability and biophysical properties were similar to those of
RBD produced in mammalian HEK-2913T cells; notably, combined with adjuvants it elicited
humoral immune response in mice12. Remarkably, the production of RBD in yeast cells is more
cost effective compared to other systems, and the fermentation bioprocess can be scaled up
under Good Manufacturing Practice conditions. We were capable of optimizing RBD expression
in P. pastoris to reach yields of 180 mg/L of ÔΩû90% pure protein, and thus were able to supply it
to the Argentinian scientific community and health system at a low cost. It is currently used as

5

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

an antigen for serological test kits, and as an immunogen. RBD could be used to produce
neutralizing antibodies at large scale in animal systems such as egg yolk (IgY)13,14 or in horses15.
While RBD is immunogenic per se, the development of a highly immunogenic antigen is
essential for the development of new generation subunit vaccines, which ideally should be
capable of simultaneously providing immunity against the different emerging RBD variants. A
possible strategy to achieve this goal is to couple the protein of interest to an immunogenic
carrier protein. Lumazine synthase (LS, EC 2.5.1.78) from Brucella abortus (BLS) is a highly
immunogenic and very stable decameric protein ideally suited to function as an immunogenic
carrier protein. Five BLS subunits (17 kDa each) form a pentamer, and two pentamers form a
very stable decamer. Such decamers may be decorated with any protein whose antigenicity needs
to be increased. The BLS decamer has been used to significantly increase the immunogenicity of
other proteins by means of the fusion between the C-terminus of the foreign protein and the
N-terminus of BLS, showing that BLS is a convenient platform for antigen display16‚Äì18.
Moreover, BLS activates dendritic cells in vitro, increasing the levels of co-stimulatory
molecules and the secretion of proinflammatory cytokines, and also recruits dendritic cells in
vivo, in both cases in a TLR4-dependent manner19. In addition, BLS chimeras are extremely
effective to rapidly activate specific CD8+ lymphocytes, and to induce significant cytotoxic
activity20. While other carrier proteins have been non-covalently attached to target proteins
through a pair of interacting proteins (e.g. X-dockerin-cohesin-Y21 where X and Y are proteins
expressed as a fusion protein with the dockerin and cohesin domains, respectively), such
non-covalent interactions might be relatively weak particularly for immunization purposes,
which normally require the use of strong adjuvants. The translational fusion of target proteins
and peptides with BLS has allowed researchers to overcome this problem22. However, given that
BLS fusions are usually expressed at high yields in Escherichia coli, this strategy may be not
adequate for proteins with a complex structure and high disulfide bonds content, and/or that
require post translational modifications, as it is the case of RBD, which cannot be properly
expressed in E. coli12. This problem could be circumvented through the covalent coupling of
RBD and BLS, in vitro, in their native state, which can be achieved with the Sortase A enzyme.
Sortase A and its variants can efficiently catalyze a transpeptidation reaction that creates a
covalent link between two native proteins or peptides23. This reaction requires that the

6

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

N-terminal protein to be covalently linked contains a specific signal located in its C-terminal
stretch: ProteinN-Leu-Pro-X-Thr-Gly (Figure 1). This site should preferably be in an
unstructured context, and the Gly residue is usually followed by a histidine tag to facilitate its
purification process. The C-terminal protein to be covalently linked should contain three Gly
amino acid residues in its N-terminal region (Gly-Gly-Gly-ProteinC). After the Sortase A
transpeptidation reaction, both subunits are joined to produce the covalently-linked product
ProteinN-Leu-Pro-X-Thr-Gly-Gly-Gly-ProteinC (Figure 1). Therefore, the Sortase A-mediated
transpeptidation reaction can couple preassembled oligomeric carriers such as BLS, or virus-like
particles (VLPs), to an immunogen expressed in a different system24. An additional advantage of
Sortase A-mediated coupling is that the scar of the transpeptidation reaction in the protein
product is of only seven residues, of which three are glycines.

7

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 1. The Strategy: Sortase A-mediated Transpeptidation Reaction. (A) The reaction is
exemplified by the coupling of a BLS subunit (red) and the SARS-Co-V2 RBD domain (green).
The enzymatic intermediary form (RBD covalent bound to Sortase A) is shown, and the
hydrolysis of the intermediary to yield the by-product RBD-Leu-Pro-Glu-Thr is included. The
latter cannot be reused in the coupling reaction. The reaction catalyzed by TEV protease to yield
Gly-Gly-Gly-BLS, the substrate of Sortase A is also shown. (B) A hypothetical reaction product
with a multiplicity of 10:10 (RBD10/BLS10) is shown.
In this work, we produced a multimeric RBD-BLS by a Sortase A-mediated transpeptidation
covalent coupling reaction between RBD expressed in P. pastoris and BLS produced in E. coli,

8

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

with the purpose of increasing RBD immunogenicity. RBD-BLS induced a strong humoral
response against SARS-CoV-2 RBD. Remarkably, the RBD antigen produced a significantly
higher humoral response when presented to the immune system in the context of an RBD-BLS
multimer with a high number of RBD molecules per particle (high multiplicity) than as a
monomer, or within low multiplicity particles. The RBD-BLS multimer is a potential vaccine
candidate, and can also be useful to produce neutralizing antibodies in animal systems. This
platform could be also used to simultaneously present several proteins to the immune system,
such as different RBD variants and other domains of the spike protein.
Results
Production of Sortase A- Substrates: BLS in E. coli and RBD in Pichia pastoris.
In order to obtain a multimeric carrier for RBD, we first produced an oligomeric form of BLS
in E. coli. For this purpose we synthesized and sequenced a gene encoding a BLS carrier protein
variant which included in its N-terminal region a TEV protease cleavage site (in italics) followed
by a Gly-tag (Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-BLS) (Figure 1). This strategy
allows the removal of the N-terminal Met after a quantitative digestion with the TEV protease,
thus producing a polypeptide carrying an N-terminal Gly-Gly-Gly required for the Sortase
A-mediated transpeptidation reaction. Following BLS expression in E. coli, the protein was
purified in two steps, by anion exchange chromatography (Q-Sepharose) followed by size
exclusion chromatography (SEC-HPLC, Superdex S200). The protein was obtained with a high
yield (100 mg L-1, >98% purity), and its identity was verified after purification by mass
spectrometry. BLS was then digested with TEV protease to generate the N-terminal Gly-Gly-Gly
motif so that it can function as a Sortase A substrate. The digestion was confirmed by
SDS-PAGE and mass spectrometry (Figures S1 and S2), which showed the expected
‚Äúactivated‚Äù multimeric carrier Gly-Gly-Gly-BLS. It is worth mentioning a complete TEV
digestion of BLS was observed.
To generate the second substrate of the coupling reaction, an RBD variant including a Sortase
A recognition signal (Leu-Pro-Glu-Thr-Gly-) followed by a (His)6-tag at its C-terminus was
produced in P. pastoris (RBD-Leu-Pro-Glu-Thr-Gly-(His)6) and obtained from culture
supernatants with a high yield (180 mg L-1, >90% purity). We have previously shown that this

9

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

protein is conformationally stable and drives a significant immune response in mice when
administered in a formulation with adjuvants25. We assessed the tertiary structure of the purified
RBD through near-UV-CD spectroscopy. The results are compatible with an asymmetric and
rigid environment of the aromatic side chains, indicating a native packing (Figures 2A and B).
Moreover, the protein does not exhibit significant aggregation, as inferred from the SEC-HPLC
profiles and the absence of species with low elution volumes (Figure 2C). In addition, as
previously observed25, SEC-HPLC analysis revealed the existence of two different species
(differing in their glycosylation patterns) with elution times compatible with molecular masses
between 45 kDa and 20 kDa.

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 2. RBD Expressed in Pichia pastoris is Properly Folded and does not Aggregate.
Near-UV Circular Dichroism Spectra of purified RBD: High tension voltage (A) and Near-UV
11

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

CD spectra (B). The protein concentration was 30 ùúáM. The buffer used was 20 mM Tris-HCl,
100 mM NaCl, pH 7.4. (C) SEC-HPLC of RBD elution profiles (monitored at 280 nm)
corresponding to two different batches (R4 and S4) of independently expressed and purified
RBD, and of molecular mass markers (158, 44, 17 and 1.35 kDa).
Native Sortase A Mediated Coupling of RBD to a Fluorescent Peptide
To evaluate the ability of recombinant RBD-Leu-Pro-Glu-Thr-Gly-(His)6 to act as a Sortase A
substrate, we first carried out a preliminary reaction using the fluorescent peptide probe
Gly-Gly-Gly-Ser-{Lys-(TMR)} as a substrate instead of BLS. This peptide contains a covalently
bound tetramethylrhodamine (TMR) label. The product of this reaction was the covalently
coupled RBD-Leu-Pro-Glu-Thr-Gly-Gly-Gly-Gly-Ser-(Lys-TMR) (RBD-TMR).
After the coupling reaction and SEC (G25) separation, nearly 17% of input RBD was labeled
with the fluorescent probe as inferred from UV and visible spectra analysis (Figures 3A and B).
The unreacted RBD retained the (His)6 tag, and could therefore be separated and recovered by
addition of NTA resin to the reaction mix followed by centrifugation. This procedure produced a
final yield of ~50% labelled RBD. Moreover, SEC-HPLC analysis, monitored at 554 nm, which
allows detection of the TMR label, revealed the presence of the reaction product. However, no
free fluorescent peptide was observed in the elution profile (Figure 3C), indicating that the G25
matrix was capable of separating the residual free peptide. SEC-HPLC (using the Superose 6
column) of the reaction product showed an absence of peaks at short elution times, suggesting
that RBD-TMR was not prone to aggregation after the covalent coupling of the probe. These
results showed that Sortase A was functional, and it was possible to carry out the covalent
coupling between recombinant RBD and a Gly-Gly-Gly-tagged substrate.

12

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 3. Covalent Coupling of RBD to a Fluorescent Probe Mediated by Sortase A. (A)
UV and (B) visible spectra of the free fluorescent probe (blue) and the coupling reaction product
RBD-TMR (green) after a G25 column separation. The RBD spectrum is also shown as a
reference (red) (C) SEC-HPLC elution profiles (Superose 6 column) of RBD (monitored at 280
nm, red), TMR (monitored at 554 nm, blue) and RBD-TMR (monitored at 554 nm, green) after
coupling and G25 separation.

13

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Functionality of Recombinant RBD
In addition to the conformational analysis, we also assessed the functionality of purified
RBD-TMR. Therefore, we tested its ability to bind RBD natural receptor during viral infection,
the human ACE2. For this purpose, we incubated (a) the labeled protein (RBD-TMR), (b) a
soluble version of ACE2 with a C-terminal (His)6 tag, and (c) agarose-NTA-Ni2+resin (Figure
4A)

during

30

min.

Next,

we

separated

the

ternary

complex

ACE2/RBD-TMR/agarose-NTA-Ni2+ by centrifugation. The matrix agarose-NTA-Ni2+ interacts
with the (His)6 tag that it is present only in the C-terminal of ACE2 (and not in RBD-TMR), thus
pulling down bound RBD-TMR and consequently producing a significant decrease of the
supernatant fluorescence intensity (570-580 nm, Figure 4B). Elution of the complex from the
NTA matrix by addition of 300 mM imidazole caused a strong fluorescence increase in the
soluble fraction, further indicating that (His)6-tagged ACE2 forms a complex with RBD-TMR
(Figure 4C). We concluded that RBD-TMR was capable of interacting with the ACE2 soluble
domain, indicating that the structural features relevant for the interaction are preserved in
recombinant RBD produced in P. pastoris, and that the conditions employed to perform the
transpeptidation reaction to produce RBD-TMR did not affect its tertiary structure.

Figure 4. Evaluation of RBD-TMR Binding to ACE2. (A) RBD-TMR pull down and
elution from the matrix. (His)6-tagged ACE2 was immobilized in an NTA matrix (300 ŒºL of
0.9 ŒºM ACE2 + 75 ŒºL of agarose-NTA-Ni2+resin). A control incubation was performed
omitting ACE2. Samples were centrifuged and washed three times and subsequently
incubated in the presence of 1 ŒºM RBD-TMR for 30 min under mild agitation. After
centrifugation, the supernatant was transferred to a fresh tube and analyzed by fluorescence
spectroscopy (B). The matrix was washed three times and eluted with 300 ŒºL of 20 mM

14

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Tris-HCl pH 8.0, 150 mM NaCl and 250 mM imidazole. The sample was centrifuged, and the
supernatant was analyzed by fluorescence spectroscopy (C). In B and C black lines
correspond to the incubation in the presence of ACE2, while red lines correspond to the
controls without ACE2. The excitation wavelength was 550 nm, the bandwidths for both
excitation and emission were of 5 nm. All the measurements were made at 25 ¬∞C.

Native Sortase A-mediated Coupling of RBD to BLS
Given that recombinant RBD proved to be a good Sortase A substrate, we proceeded to
attempt

the

coupling

of

RBD-Leu-Pro-Glu-Thr-Gly-(His)6

and

TEV-digested

Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-BLS. The expected product was the covalently
coupled RBD-Leu-Pro-Glu-Thr-Gly-Gly-Gly-Gly-Ser-Gly-Ser-Gly-BLS (RBD-BLS in Figure
1). The SEC-HPLC profiles (Superose 6 column) corresponding to a BLS multimer, RBD alone
and the reaction product are shown in Figure 5A. The product of the covalent coupling mediated
by Sortase A exhibited an elution time compatible with an increment in the hydrodynamic radius
of the assembly compared to that observed for the decameric BLS (27 and 31.5 min,
respectively). The unreacted BLS decamer and RBD are also clearly distinguishable in the SEC
profile.
Since BLS is a decameric protein, different multiplicities (RBD n/BLS10) can be obtained
depending on the buffer conditions and the stoichiometry of the Sortase A reaction. It was
possible to obtain different multiplicities by controlling RBD and BLS concentration ratios. We
used low RBD and high BLS concentration, to obtain low multiplicities (between 1 and 2 of
RBD copies per multimer, Figure S3), referred as RBD-BLS LM), whereas the higher
multiplicities (referred as RBD-BLS HM) were obtained with higher RBD/BLS ratios (Figure
S3 and Figure 5A).
To determine such multiplicities, and given that the presence of heterogeneous sizes of glycan
moieties in RBD resulted in a high heterogeneity which difficults the analysis, we trimmed the
glycans with endoglycosidase H and resolved the deglycosylated products of the coupling
reaction by SDS-PAGE (Figure 5B, compare lanes 1 and 3 to 2 and 4). The sharp band that
migrates close to the 40 kDa marker in lane 3 corresponds to the covalently coupled RBD-BLS
(26 kDa of deglycosylated RBD +17 kDa of monomeric BLS, 43 kDa, Lane 1). It should be

15

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

noted that a large amount of RBD still remains uncoupled (blue arrow in Lane 3), therefore the
efficiency of the reaction still needs to be improved. Additionally, a byproduct (between 15-18
kDa) was observed that still needs to be identified (lanes 3 and 4).
A quantification of the loss of free BLS and the increment of the RBD-BLS band in
SDS-PAGE (and HPLC) allowed us to quantify the yield and the multiplicity (Figure S4), that is
the number of RBD copies per RBD-BLS particle, of the coupling reaction. We have obtained
preliminary yields of 10-30% with average multiplicities between 2 and 4 (RBD2/BLS10 and
RBD4/BLS10, respectively) in preliminary experiments. However, the incorporation of a
concentration step (the reaction made in a centrifugal filter unit (Centricon, Merck Millipore)
with a cutoff of 10 kDa, see Materials and Methods for details) allowed us to enhance the
reaction, yielding in higher multiplicities (between RBD6./BLS10 and RBD7./BLS10, RBD-BLS
HM).
In summary, we succeeded in coupling the eukaryotic-produced RBD antigen with the E.coli
expressed decameric carrier BLS under native conditions. In addition, the possibility of
obtaining RBD-BLS with different multiplicities allowed to study the effect of multiplicity on
the development of the immune response.

16

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure. 5. Sortase A-mediated Covalent Coupling of RBD and BLS. (A) SEC-HPLC profiles
corresponding to Gly-Gly-Gly-BLS (black), RBD (red), the control reaction mixture without
Sortase A (violet) and the product of the reaction catalyzed by Sortase A, (green, lower panel).
An equivalent volume of a 10 mM EDTA, 10 mM CaCl2 solution was loaded as a control
17

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

(magenta, lower pane). Decameric BLS has a molecular weight of approximately 170 kDa and
each RBD subunit adds approximately 26 kDa or 40 kDa (excluding or including glycosylation,
respectively). The observed multiplicity was ~6.6 (RBD6.6/BLS10) with a yield of ~20%. The
RBD-BLS oligomer eluted at ~25 min. The peak observed between 38-43 min corresponds to
EDTA-Ca2+. Sortase A requires 10 mM CaCl2 for the activation of its catalytic activity, therefore
10 mM EDTA was added to stop the reaction, which was carried out during 240 min at 4 ¬∞C. (B)
SDS-PAGE analysis of Sortase A-mediated RBD-BLS coupling. To facilitate the detection of the
Sortase A reaction products, the protein samples were treated or not with endoglycosidase H.
Lanes 1-2: RBD + BLS without Sortase A, deglycosylated (lane 1), or not (lane 2), Lanes 3-4:
RBD+BLS after reaction with Sortase A, deglycosylated (lane 3) or not (lane 4).

Once purified by SEC, the coupling product was found to be stable after freezing and
subsequent thawing, and did not show any significant aggregation tendency. In addition, the
product could be easily concentrated, and did not show any apparent interaction with the
concentrator membranes (data not shown). Importantly, the coupling products were also
separated from the Sortase A enzyme by SEC. This is an essential step to avoid reverse
transpeptidation and RBD-Sortase A hydrolysis (that would result in a RBDh product that can
not be recycled by the enzyme)26, which would reduce the global yield of the reaction.

The Immunogenicity of RBD is Increased by Coupling to the BLS multimer.
To assess whether RBD coupled to BLS can improve the immunogenicity of RBD, we
immunized mice with two doses of RBD-BLS HM, RBD-BLS LM and monomeric RBD, 30
days apart (Table 1, Materials and Methods). In addition, RBD and RBD-BLS-HM formulations
were adjuvanted with Al(OH) 3.
The multimeric RBD-BLS HM formulation alone elicited a strong humoral response with
high anti-RBD IgG titers, and when adjuvanted with AL(OH)3 the humoral response increased
6.75 times relative to RBD-BLS HM alone (Figure 6). By contrast, monomeric RBD did not
elicit a significant anti-RBD IgG specific antibody response even in presence of Al(OH) 3. We
also observed that the addition of BLS to monomeric RBD (at the same BLS concentration used
in the case of RBD-BLS HM) slightly improved humoral immune response (RBD + BLS
group).This result suggests that BLS showed some adjuvant ability per se. Furthermore, the
multiplicity of RBD-BLS multimers turned out to be a key variable, since a high multiplicity

18

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

elicited strong immune response, while a low multiplicity did not (RBD-BLS LM group,
between 1 and 2 copies of RBD per multimer).
These results clearly show that coupling of RBD to BLS at high multiplicity strongly
enhances RBD immunogenicity, which might be due at least in part to the spatial arrangement of
the RBD subunits in the resulting particles (Figure 1B).

Figure 6. RBD-specific Humoral Immune Response in Mice Vaccinated with Monomeric
RBD and RBD-BLS Multimers. A) Immunization scheme and blood collection. BALB/c mice
(n=5) were vaccinated with two doses of the formulations 30 days apart subcutaneously and
sera were obtained 20 days after boost. B) Evaluation of anti-RBD IgG antibody titers. Serial
dilutions of sera samples were dispensed in a multi-well plate and RBD-specific IgG titers were
determined by ELISA at day 50. Multiplicity (RBD/BLS), presence (500 Œºg) or absence of
19

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Al(OH)3 adjuvant, and whether or not BLS is covalently bound to RBD is indicated. The results
are expressed as mean endpoint titers. The S.E.M. is indicated by vertical lines. Differences were
statistically significant at p<0.05 (*).

Immunization with BLS-RBD Elicit Antibodies with Neutralizing Activity Against a
SARS-CoV-2 S Pseudotyped Virus Transduction
To analyze the neutralizing activity of immune sera elicited by RBD-BLS immunization, in
vitro neutralization assays using SARS-CoV-2 S pseudotyped lentiviruses were performed27.
Serial dilutions (1:100; 1:500; 1:2,500; 1:12,500; 1:62,500; 1:312,500; 1:1,562,500;
1:7,812,500) of sera were made in the DMEM medium and incubated with equal amounts of
pseudotyped virus, then added to HEK-293T cells previously transfected with ACE2 and
TMPRSS2 protease. While pseudotyped virus particles were capable of delivering
GFP-encoding RNA into the cells in the presence of preimmune serum, immune sera prevented
transduction, shown as a percentage of inhibition, in a concentration-dependent manner. Sera
from mice immunized with RBD-BLS HM (Table 1), strongly reduced the number of
GFP-expressing cells (Figure 7). Remarkably, immunizations with RBD-BLS HM administered
in the presence of Al(OH)3 adjuvant resulted in significantly higher neutralizing antibody titers
(Figure 7, IC50 values are 8700 and 2132, with and without adjuvant, respectively), as judged by
the significant reduction observed in pseudotyped virus transduction. By contrast, sera from
mice immunized with Pichia pastoris-expressed RBD domain plus BLS (not covalently
coupled) resulted in lower neutralizing antibody titers (IC50 = 356.2, Table 1, RBD + BLS).
Altogether these results show that RBD-BLS HM is a very promising candidate both to
induce neutralizing antibodies in animal models, and as a candidate for a protein-based vaccine.

20

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Figure 7. SARS-CoV-2 S Pseudotyped Virus Neutralization Assay. HEK-293T cells
transfected with ACE2 and TMPRSS2 protease were transduced with aSARS-CoV-2 S
pseudotyped lentivirus carrying a GFP-encoding mRNA in the presence of different dilutions of
mouse sera. Forty eight hours later, cells were observed under the microscope. The number of
GFP positive cells for each serial dilution was relativized to normal-serum control. The serum
antibody dilution causing a 50% reduction of GFP positive cells (IC50) compared to control
‚Äúvirus only‚Äù treated cells was calculated using Graphpad Prism.

Discussion
A year ago, just before SARS-CoV-2 was first detected in Argentina, a group of researchers
from different institutions and with different relevant expertises joined forces to help fighting the
ongoing pandemic. Our work aimed to produce the RBD domain of SARS-CoV-2 spike protein,
as it is a useful tool for the serological detection of infected patients, and has the potential to be
used as antigen to develop a low cost vaccine. So far we have successfully produced RBD in
different expression systems, among them in the yeast P. pastoris, which showed biophysical
properties similar to that of RBD expressed in mammalian cells25.
In this work RBD was covalently coupled to a multimeric carrier with the aim of improving
its immunogenicity to develop a useful vaccine candidate. As a carrier we used the multimeric
lumazine synthase protein from Brucella abortus (BLS), which has been previously shown to be

21

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

a good antigen carrier for systemic immunization and as mucosal-adjuvant, which makes it a
good candidate to be used for oral subunit vaccines17. We have improved the efficiency of the
RBD-BLS coupling reaction to scale up the production and purification of the RBD-BLS
oligomer, obtaining different multiplicities (1 to 6) and we have compared the immunogenicity
of RBD-BLS vs. RBD in mice.
Our results showed that the RBD-BLS multimer can elicit an increased immune response
compared to that of monomeric RBD, even in the absence of adjuvant. This increase depended
on the covalent coupling of RBD to BLS, as the co-administration of RBD with BLS (i.e. not
covalently coupled) did not induce an equivalent immune response. We also observed that the
multiplicity of RBD coupled to BLS was an important factor in the enhancement of the
immunological response.
In immunological studies we observed that RBD coupled to BLS at a high multiplicity (6-7
RBD copies per BLS decamer) is remarkably more immunogenic than monomeric RBD, or than
RBD coupled to BLS at a low multiplicity (1-2 RBD copies per BLS decamer). An 80-fold
increment in the anti-RBD humoral immune response was observed by RBD-BLS HM
compared to monomeric RBD. By contrast, no significant

humoral immune response was

elicited by monomeric RBD in the presence or absence of Al(OH)3, or by the addition of BLS to
RBD (without covalent coupling). In addition, when Al(OH)3 was added to RBD-BLS HM an
extra 6.75-fold increase in total anti-RBD IgG titer and 4.1 fold increase in sera neutralization
IC50 value was observed.
Whereas BLS is highly resistant to urea-induced unfolding, the decameric structure is
sensitive to low pH (pH 4.0-5.5), or to moderate guanidinium chloride concentrations (2.0 M)28,
which cause the dissociation of the decameric forms to pentamers. In addition, BLS has been
previously modified, and several pentameric variants also exist that could be used to assemble
pentamers, which could then be mixed to obtain the decameric form, taking advantage of surface
complementation that depends on the new side-chain residues on these surfaces29. This makes
BLS a very malleable protein, and would allow, for example, to include different immunogens in
the same protein particle. BLS oligomers carrying different coupled proteins could be
disassembled by incubation at low pH, mixed and reassembled so as to generate a diversity of
homo and hetero decamers. As a Toll-like receptor (TLR) agonist, it has been shown that BLS

22

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

can stimulate both innate and adaptive immune responses, thereby improving vaccine
efficacy17,20. Thus RBD-BLS, alone or in combination with adjuvants, has the potential to boost
T- and B-cell responses against SARS-CoV-2, which deserves further exploration.
The idea of coupling RBD to a multimeric protein to produce a stronger immunogen has been
considered by other groups. Some molecular platforms have been proposed to multimerize CoV
antigens. A very interesting recent work reports the production of particles displaying regions of
the Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein, by coupling its
RBD domain to a multimeric lumazine synthase (LS), using the SpyTag/SpyCatcher system 30, in
which the peptide SpyTag that includes 13 amino acids reacts with the 12.3 kDa-SpyCatcher
protein31. A similar strategy has been recently developed by Hang and coworkers for
SARS-CoV-2 spike protein using both Aquifex aeolicus LS and Helicobacter pylori ferritin as
nanoparticle scaffolds32. They coupled a trimeric version of the antigen to LS, which caused such
nanoparticles to elicit significantly higher neutralizing antibody responses than the spike protein
alone. New strategies to develop novel vaccines against SARS-CoV2 also include
self-assembling fusion proteins. For example, Powell and coworkers have recently prepared in
Expi293F mammalian cells a fusion protein containing the spike ectodomain followed by H.
pylori ferritin, a 19 kDa protein that self-assembles into a 24-subunit nanoparticle33. Of note,
such nanoparticles display eight copies of a trimeric antigen on the surface, as previously used
for haemagglutinin from H1N1 virus34. The authors showed that multivalent presentation of
spike trimers on ferritin can notably increase elicitation of neutralizing antibodies in mice after a
single dose.
In this context, the strategy presented here involving RBD-BLS particles may be considered
as a new useful tool against SARS-CoV-2. The platform is ductile enough to incorporate new
variants like E484K, which has been associated with escape from neutralizing antibodies 35‚Äì37 or
N501Y, which is associated with increased binding specificity and faster-growing lineages 38.
This is important given the high chance of having new waves of SARS-CoV-2 involving RBD
mutant viruses.

23

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Materials and Methods
SARS-CoV-2 RBD Protein Expression and Purification
The receptor binding domain of spike protein from SARS-CoV-2 (RBD) was expressed in
Pichia pastoris. The RBD coding sequence (spike amino acid residues 319-537) was fused to the
Saccharomyces cerevisiae alpha factor secretion signal (N-terminal) followed by a C-terminal
Sortase A recognition sequence and a His6 tag (C-terminal) given the C-terminal sequence
RBD-Leu-Pro-Glu-Thr-Gly-(His)6 as previously reported25. The expression was carried out in a
bioreactor as indicated, and the protein was purified with a yield of 150 mg L-1 of culture
supernatant25. RBD concentration was determined by UV spectrophotometry using an absorption
coefficient of 33850 M-1 cm-1.
BLS Expression and Purification
A gene encoding a variant of lumazine synthase of Brucella abortus (BLS) including an
N-terminal TEV site followed by a Gly-Gly-Gly sequence and a Gly-Ser-GLy-Ser-GLy spacer
(Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-Gly-Ser-GLy-Ser-Gly-BLS) was assembled and
cloned in the pET11a vector (Novagen). The construct was checked by sequencing. The protein
was expressed in E. coli BL21(DE3). Cells were grown in Luria Bertani broth at 37 ¬∫C to OD600
1.0, and protein expression was induced by 1 mM IPTG. Expression was carried out at 28 ¬∫C
overnight. The cells were harvested by centrifugation at 6,000 rpm for 20 min and freezed at -20
¬∫C until use. The cell pellet was resuspended in 20 mL of 20 mM Tris-HCl, pH 7.4 and gently
sonicated in an ice-water bath. The sample was centrifuged at 10,000 rpm for 30 min, and the
soluble fraction was transferred to a fresh tube. The protein was purified in two steps. First the
soluble fraction was loaded onto an anionic exchange chromatographic column (Q-Sepharose,
given that the theoretical pI value of BLS is 6.4). The fractions containing BLS, as judged by
SDS-PAGE analysis, were pooled and loaded onto a size exclusion chromatographic column
(Superdex S200). Fractions containing BLS were pooled and the purified protein was analyzed
by mass spectrometry and SDS-PAGE. BLS concentration was determined by UV
spectrophotometry using an absorption coefficient of 18405 M-1 cm-1.

24

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

ACE2 Expression and Purification
The expression plasmid pcDNA3-sACE2(WT)-8his, which includes the human ACE2 soluble
domain (residues 1-615) coding gene, followed by a Gly-Ser-Gly linker and eight His residues
for purification, was transfected in HEK-293T mammalian cells. Cells were grown in high
glucose (4.5 g L-1) Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum (FBS, Natocor), 110 mg L-1 of sodium pyruvate
(Thermo Fisher Scientific) and penicillin/streptomycin (100 units mL-1 and 100 Œºg mL-1
respectively, Thermo Fisher Scientific) in a 37 ¬∞C incubator under 5% CO2. Cells were plated
(2x107 cells per 150 mm plate) and grown for 24 h before transfection with Polyethylenimine
(PEI, Sigma). After 72 h, the cell culture medium was centrifuged twice at 12,000 √óg for 20 min
at 4 ¬∞C. The supernatant pH was adjusted to pH 8.0 with an equilibration buffer (50 mM sodium
phosphate, 300 mM NaCl and 20 mM imidazole, pH 8.0). Soluble ACE2 was purified using a
previously equilibrated Ni

2+

-NTA-agarose column. The protein was eluted by increasing

imidazole concentrations (prepared in the equilibration buffer). Fractions containing the ACE2,
as judged by the SDS-PAGE analysis, were pooled and dialyzed against a buffer without
imidazole (20 mM sodium phosphate, 150 mM NaCl, pH 7.4). pcDNA3-sACE2(WT)-8his was a
gift

from

Erik

Procko

(Addgene plasmid # 149268; http://n2t.net/addgene:149268;

RRID:Addgene_149268)39, and the HEK-293T mammalian cell line was kindly provided by
Xavier Saelens (VIB-University of Ghent, Belgium). ACE2 concentration was determined by
UV spectrophotometry using an absorption coefficient of 157220 M-1 cm-1.
TEV Protease Expression and Purification
Tobacco Etch Virus protease (TEV) was a gift from Helena Berglund (Addgene plasmid #
125194 ; http://n2t.net/addgene:125194 ; RRID:Addgene_125194)40. Briefly, E coli Rosetta
(DE3) cells (starting with a 1/20 dilution of an overnight pre-culture) were grown in Luria
Bertani media at 37 ¬∫C up to OD600nm of 0.6. TEV was induced (for 4 h at 37 ¬∫C) by the addition
of 0.5 mM IPTG. Cells were centrifuged, resuspended, and sonicated in 20 mL of lysis buffer
(50 mM phosphate pH 8.0, 150 mM NaCl, 20 mM Imidazole, 10% glycerol). The sample was
subsequently centrifuged, and the soluble fraction loaded in a NTA-Ni2+ agarose column
previously equilibrated with the lysis buffer. A washing step with 10 column volumes was
performed, and the protein was eluted with 2.5 volumes of elution buffer (50 mM phosphate pH

25

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

8.0, 150 mM NaCl, 250 mM Imidazole, 10% glycerol). Finally, to remove imidazole, the protein
was subjected to dialysis and stored at -80 ¬∫C in small fractions.
Sortase A Expression and Purification
The Sortase A pentamutant (eSrtA) in pET29 was a gift from David Liu (Addgene plasmid #
75144 ; http://n2t.net/addgene:75144; RRID:Addgene_75144)41. Briefly, E. coli BL21 (DE3)
cells (starting with a 1/40 dilution of an overnight pre-culture) were grown in Terrific Broth at 37
¬∫C up to OD600nm of 0.6. Sortase A expression was induced for 5 h at 37 ¬∫C by the addition of 1
mM IPTG. Cells were centrifuged, resuspended, and sonicated in 35 mL of lysis buffer (50 mM
Tris-HCl pH 8.0, 150 mM NaCl, 20 mM Imidazole, 10% glycerol). After that the sample was
centrifuged and the soluble fraction loaded in NTA-Ni2+ agarose previously equilibrated with the
lysis buffer. A washing step with 10 column volumes was performed and the elution was carried
out with 2.5 volumes of elution buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 350 mM
Imidazole, 10% glycerol). Finally, imidazole was removed and the protein was concentrated
using a Centricon (Merck Millipore) and preserved at -80 ¬∫C in small fractions at 2 mM
concentration.
ESI MS for Intact Mass Analysis
The protein samples were analyzed on an LC‚àíESI-MS platform consisting of a Surveyor MS
pump system (C4 column, Higgins Analytical Proto 300 5¬µm RS-0301-W045, 30 mm √ó 1.0
mm) coupled to an electrospray mass spectrometer (Thermo Finnigan LCQ duo, equipped with
an ion trap mass analyzer). The gradient was 5% solvent B (96% acetonitrile, 2% acetic acid) in
solvent A (2% acetonitrile, 2% acetic acid) for 2 min, 5 to 100 % solvent B in solvent A in 4
min, and 100% solvent B for 8 min at a flow rate of 40 ŒºL min-1. The ESI spectra was
deconvoluted to the zero-charge domain by the ProMass Deconvolution Software (Novatia)
using a standard parameter set: average mass type, mass tolerance 0.02%, minimum tolerance 2
Da and input m/z range 500‚àí2000 units.

Circular Dichroism Spectroscopy
CD spectra measurements were carried out at 20 ¬∞C with a Jasco J-815 spectropolarimeter.
Near-UV CD spectra were collected using cells with path lengths 1.0 cm. High tension voltage
was registered simultaneously. Data was acquired at a scan speed of 20 nm min-1 (five scans

26

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

were averaged, scans corresponding to buffer solution were averaged and subtracted from the
spectra). Values of ellipticity were converted to molar ellipticity.
Fluorescent Probe
The

tetramethylrhodamine

(TMR)

labeled

peptide

with

sequence

Gly-Gly-GLy-Ser-{Lys-(TMR)}was purchased from Genscript. Its mass, as determined by mass
spectrometry analysis, and excitation and emission spectra were compatible with the predicted
theoretical values. An absorption coefficient of 87500 M-1 cm-1 at 560 nm was used to calculate
the TMR concentration in solution. To evaluate the transpeptidation efficiency, a spectrum of
free TMR was subtracted from the spectrum of protein in order to correct the 280 nm absorbance
value of the protein solution.
Transpeptidation and Multiplicity
The transpeptidation reaction was performed by the Sortase A enzyme. To obtain a product
with high multiplicity (6:10, RBD:BLS) 70 and 35 ùúáM of RBD and BLS respectively were used.
For lower ratios (approximately 2:10, RBD:BLS), 70 and 350 ùúáM of RBD and BLS respectively
were used. The reaction was started by the addition of Sortase A (0.4 ùúáM final concentration
from a 2 mM stock solution preserved at -80 oC). The reaction was performed in a 20 mM
Tris-HCl, 150 mM NaCl, pH 7.4, 10 mM CaCl2 buffer. CaCl2 allowed the activation of Sortase
A, therefore the reaction was stopped by the addition of 10 mM EDTA. The reaction previously
treated or not with 5 mU of endoglycosidase H during 1 h at 37 oC was analyzed by SDS-PAGE
and by SEC-HPLC. In order to improve the efficiency and the irreversibility of the
transpeptidation

reaction,

one

of

the

reaction

products,

the

short

peptide

Gly-His-His-His-His-His-His splitted by Sortase A from the C-terminal of RBD (Figure 1 for
reference), was extracted from the mixture. For this purpose, we performed the reaction in a
concentrator of 10 kDa cutoff under centrifugation at 3000 rpm at 4 oC. Control experiments
were performed without centrifugation. All samples were kept at 4 ¬∞C.
Hydrodynamic Behavior of the Proteins
Size exclusion chromatography (SEC-HPLC) was carried out using a Superose-6 column (GE
Healthcare). The protein concentration was 10-30 ŒºM, a volume of 50 ŒºL was typically injected,
and the running buffer was 20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.0. The

27

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

experiment was carried out at room temperature (‚àº25 ¬∫C) at a 0.5 mL min-1 flow rate. A JASCO
HPLC instrument was used. It was equipped with an automatic injector, a quaternary pump and a
UV-VIS UV-2075 (the elution was monitored at 280 nm).
Interaction between Recombinant RBD and ACE2.
The interaction between the covalently coupled product RBD-TMR and the ACE2 soluble
domain was studied taking advantage of the presence of a (His)6 tag in the C-terminus of ACE2,
which is not present in RBD-TMR. ACE2 (1.0 ŒºM) and RBD-TMR (1.0 ŒºM) were incubated
during 30 min, with gentle agitation in darkness in the presence of NTA-Ni2+ in 20 mM sodium
phosphate, 150 mM NaCl, pH 7.40. The complex was separated from free RBD-TMR by
centrifugation (1 min at maximum speed in a microcentrifuge). The fluorescence after the
incubation was measured using an excitation wavelength of 560 nm, the emission monitored
between 570 and 670 nm, a 4 nm bandwidth was used for both excitation and emission.
Measurements were performed in a JASCO spectrofluorometer equipped with a thermostated
cell holder connected to a circulating water bath set at 25 ¬∫C. A path length cell of 0.3 cm was
used. Additionally, the complex bound to the NTA matrix was eluted by the addition of
imidazole and the fluorescence of the supernatant was analyzed in the same fashion.
Endotoxin Remotion and Detection
Lipopolysaccharide (LPS)42 was removed from the protein preparations by an overnight
incubation (4 ¬∫C) of the proteins with polymyxin B matrix followed by a second incubation (2-3
h) at room temperature. The matrix was previously equilibrated in 20 mM Tris-HCl, 100 mM
NaCl, pH 7.0 buffer solution. We measured the LPS content of purified RBD-BLS preparations
as previously described19. The endotoxin concentration in the protein samples was determined by
Cassar√° Fundation Laboratories. Briefly, all protein samples were brought to a final volume of
200 ŒºL and the LPS content was measured using a commercial kit from Charles River Endosafe
(R160), based on the Limulus amebocyte lysate (LAL) assay chromogenic method, with a
sensitivity of 0.015 EU/ml. No LPS was detected in the RBD-BLS preparation following
endotoxin removal.
Immunization Protocols
Mice immunization was carried out by experts from the High Level Technological Service

28

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

from CONICET (STAN No. 4482), under guidelines from the Institutional Committee for the
Care and Use of Laboratory Animals (CICUAL). BALB/c mice were obtained from the animal
facility of the Faculty of Veterinary Sciences, University of La Plata (Argentina), and housed at
the animal facility of the Instituto de Ciencia y Tecnolog√≠a Dr. C√©sar Milstein, Fundaci√≥n Pablo
Cassar√°. Six groups of five Females mice (6-8 week-old) (n=5) were immunized subcutaneously
with the same amount of RBD protein (15 ¬µg) coupled or not to BLS in the presence or absence
of 500 ¬µg aluminum hydroxide (Al(OH)3). Two different BLS coupling formulations were
obtained (Table 1): RBD6.6/BLS10 (high multiplicity, RBD-BLS HM) and RBD1.5/BLS10 (low
multiplicity, RBD-BLS LM). Additionally, uncoupled RBD + BLS formulation (RBD + BLS,
Table 1) was tested with the same equimolar conditions used for the RBD-BLS HM group.
Pre-immune sera also were collected before starting the immunization. Mice received two
immunizations with the same dose at days 0 (antigen prime) and 30 (antigen boost). Additional
control animals were injected with 500 ¬µg Al(OH)3 per mouse with the same immunization
schedule.
Blood samples were obtained at 20 days post-second immunization by venipuncture from the
facial vein. After coagulation at room temperature for 1-2 h, blood samples were spun in a
centrifuge at 3000 rpm/min for 10 min at 4 ¬∞C. The upper serum layer was collected and stored
at -20¬∞C.
Table 1. Immunization Treatments.
Groups

RBD
(ùúág/dose)

BLS
(ùúág/dose)

Covalent
coupling

RBD: BLS
(molar ratio)

Adjuvant
(Al(OH)3)

RBD

15

0

---

---

No

RBD

15

0

---

---

Yes

RBD + BLS

15

17

No

6.6:10

No

RBD-BLS LM

15

70

Yes

1.5:10

No

RBD-BLS HM

15

17

Yes

6.6:10

No

RBD-BLS HM

15

17

Yes

6.6:10

Yes

29

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

Identification of Serum Antibody Against Protein RBD in Mice Using an ELISA Assay.
The antibody response against RBD and RBD-BLS was measured using a standard ELISA
procedure. Briefly, flat-bottom 96-well plates (Thermo Scientific NUNC-MaxiSorp) were coated
with recombinant RBD protein produced in P. pastoris at a final concentration of 1 ¬µg/ml (100
¬µl/well) in phosphate-buffered saline (PBS) coating buffer (pH 7.4) at 4 ¬∞C overnight. After
blocking (8% nonfat dry milk PBS for 2 h at 37 ¬∞C) the plates were washed 5 times with PBS
containing 0.05% Tween 20 (PBST). Serially diluted mouse sera were incubated at 37 ¬∞C for 90
min in PBS containing 1% non-fat dry milk (blocking solution), and plates were subsequently
washed with PBST. For total specific IgG determination, IgG horseradish peroxidase
(HRP)-conjugated antibody (DAKO P0447) was diluted 1/1000 in blocking solution and added
to the wells. After incubation for 1 h at 37 ¬∞C, plates were washed fivetimes with PBST and
developed with 3,3‚Äô,5,5‚Äô-tetramethylbiphenyldiamine (TMB) for 15 min. The reaction was
stopped with 50 ¬µl/well of 1 M H2SO4 (stop solution). The absorbance was measured in a
microplate reader (Thermo Multiscan FC ELISA) at 450 nm.
The antibody titer was determined as the inverse of the last dilution that was considered
positive, with a cut-off value defined as absorbance at 450 nm of 0.20, which was twice as high
as that from a pool of normal mouse sera (from 30 unimmunized animals). Statistical
significance was evaluated by the Student‚Äôs t-test, using a logarithmic transformation of the
ELISA titers. Differences were considered significant if p < 0.05.
Pseudotyped Lentivirus Neutralization Assay
SARS-CoV-2 S-Pseudotyped lentivirus27,43 were produced by co-transfection of HEK-293T
cells with plasmids bearing a GFP reporter gene (pLB was a gift from Stephan Kissler, Addgene
plasmid #11619; http://n2t.net/addgene:11619; RRID:Addgene_11619), a lentivirus backbone
(VRC5602, NIH), and the Spike protein (VRC7475_2019-nCoV-S-WT, NIH). Briefly,
HEK-293T cells (2√ó107) were seeded in a 150-mm tissue culture dish in DMEM medium
containing 10% FBS. The next day, cells were transfected with 10 Œºg of VRC5602, 5 Œºg
pLB-GFP, and 3 Œºg of VRC7475_2019-nCoV-S-WT in OptiMEM medium using PEI in a 1:3
DNA:PEI ratio. Twenty four hours later, transfection efficiency, indicated as GFP fluorescence,
was checked under a fluorescent microscope. Pseudotyped lentivirus supernatants were

30

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

harvested 48 h post-transfection and stored at 4 ¬∞C, fresh media (DMEM + 5% FBS) was added
to the plates. After 48 h, combined supernatants were clarified by centrifugation for 10 min at
3,000 rpm to pellet the residual cells. The clarified supernatant was centrifuged for 5 h at 10,000
rpm. The pellet was resuspended in a storage medium (OptiMEM + 6% Sucrose) and aliquots
were frozen at -80 ¬∞C until use.
Pseudotyped lentivirus titers were measured by transducing HEK-293T cells previously
seeded in 96-well plates (2x104 cells/well) and transiently transfected with 100 ng of ACE2
(NIH) and 10 ng of TMPRSS2 protease (NIH) per well. The pseudotyped virus stock
(concentrated supernatant) was serially diluted in assay medium (DMEM + 2.5% FBS),
incubated for 2 h at 37 ¬∞C and added to the transfected cells. Virus titers were calculated by
counting the GFP positive cells using an automated counting tool in ImageJ (NIH), a titer of
200-225 GFP positive cells/field using 100X magnification was used for the assay.
Neutralization assays were performed on HEK-293T cells transiently transfected 24 h before
transduction with ACE2 and TMPRSS2 protease genes. Fifty microliters of serial 5-fold diluted
heat-inactivated serum (56 ¬∞C for 45 min), starting dilution of 1:100, were prepared in assay
medium and incubated for 2 h with an equal volume of titrated pseudotyped lentivirus.
Pseudovirus and sera dilution mixtures (100 Œºl) were then added onto 96-well plates containing
2x104 cells/well. Pseudovirus infectivity was scored 48 h later and images were obtained using
an inverted microscope (IX-71 OLYMPUS), and analyzed with the Micro-Manager Open Source
Microscopy Software. Sera antibody neutralization titers were calculated by a nonlinear
regression curve fit using GraphPad Prism software Inc. (La Jolla, CA). Half maximal inhibitory
concentration (IC50), corresponding to the serum antibody dilution causing a 50% reduction of
GFP positive cells compared to control ‚Äúvirus only‚Äù treated cells, was determined using the same
software according to Ferrara and Temperton 44.
Acknowledgments
We thank LANAIS-PRO-EM for the support with mass spectrometry analysis of proteins and
peptides, and Fundaci√≥n Ciencias Exactas y Naturales from Universidad de Buenos Aires for
their help. Also we would like to thank Santigo Sosa for suggestions concerning BLS and Dr.
Fernando Goldbaum for providing us a BLS variant without Cys residues. We thank Erik Procko
for providing us with pcDNA3-sACE2(WT)-8his (Addgene plasmid #149268), Stephan Kissler

31

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

for providing us with pLB (Addgene plasmid #11619) and David Liu for providing us with
Sortase A pentamutant (Addgene plasmid #75144).
Author Contributions
All authors from the Argentinian AntiCovid Consortium (*) designed experiments, performed
research, analyzed data and drafted the manuscript. All authors (listed in alphabetical order)
contributed equally to this work. P. C. F. determined endotoxin contents in the protein samples
prior to the formulation for immunizations.
Competing interests
The author(s) declare no competing interests.
Funding Sources
This study was supported by the Agencia Nacional de Promoci√≥n de la Investigaci√≥n, el
Desarrollo Tecnol√≥gico y la Innovaci√≥n (ANPCyT) (IP-COVID-19-234), Consejo Nacional de
Investigaciones Cient√≠ficas y T√©cnicas (CONICET), Universidad de Buenos Aires (UBA,
PIDAE 2019) and Universidad Nacional de San Mart√≠n (UNSAM). We would like to thank the
following Institutions for supporting M.F. Pavan and N.B.F. (CONICET), T.I.H. (ANPCyT) and
M.F. Pignataro (F.A.R.A.).
UniProt Accession IDs
UniProtKB - P0DTC2 (SPIKE_SARS2); Spike glycoprotein from SARS-CoV-2.
UniProtKB - Q2YKV1 (RISB2_BRUA2); 6,7-dimethyl-8-ribityllumazine synthase 2.
UniProtKB - Q9BYF1 (ACE2_HUMAN); human angiotensin-converting enzyme 2.

References
1. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516‚Äì527 (2020).
2. Sharma, O., Sultan, A. A., Ding, H. & Triggle, C. R. A Review of the Progress and
Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 11, 2413 (2020).
3. Chen, W.-H. et al. Genetic modification to design a stable yeast-expressed recombinant

32

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim.
Biophys. Acta BBA-Gen. Subj. 129893 (2021).
4. Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to
zoonotic coronaviruses in mice. Science 371, 735‚Äì741 (2021).
5. da Silva Francisco Jr, R. et al. Pervasive transmission of E484K and emergence of
VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages
in Rio Grande do Sul, Brazil. Virus Res. 198345 (2021).
6. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus. Nature 426, 450‚Äì454 (2003).
7. Brouwer, P. J. et al. Potent neutralizing antibodies from COVID-19 patients define
multiple targets of vulnerability. Science 369, 643‚Äì650 (2020).
8. Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of
SARS-CoV-2. Nature 584, 120‚Äì124 (2020).
9. Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581,
221‚Äì224 (2020).
10.

Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific

glycan analysis of the SARS-CoV-2 spike. Science 369, 330‚Äì333 (2020).
11.

Shajahan, A., Supekar, N. T., Gleinich, A. S. & Azadi, P. Deducing the N-and

O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.
Glycobiology 30, 981‚Äì988 (2020).
12.

Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel

coronavirus: implication for development of RBD protein as a viral attachment inhibitor
and vaccine. Cell. Mol. Immunol. 17, 613‚Äì620 (2020).
13.

Wei, S. et al. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple

33

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

SARS-CoV-2 spike protein variants to human ACE2. Int. Immunopharmacol. 90, 107172
(2021).
14.

Lu, Y. et al. Generation of Chicken IgY against SARS-COV-2 Spike Protein and

Epitope Mapping. J. Immunol. Res. 2020, (2020).
15.

Zylberman, V. et al. Development of a hyperimmune equine serum therapy for

COVID-19 in Argentina. (2020).
16.

Hiriart, Y. et al. Characterization of structural and immunological properties of a

fusion protein between flagellin from Salmonella and lumazine synthase from Brucella.
Protein Sci. 26, 1049‚Äì1059 (2017).
17.

Rosas, G. et al. Brucella spp. lumazine synthase: a novel adjuvant and antigen

delivery system to effectively induce oral immunity. Microbes Infect. 8, 1277‚Äì1286 (2006).
18.

Alfano, E. F. et al. Expression of the multimeric and highly immunogenic Brucella

spp. lumazine synthase fused to bovine rotavirus VP8d as a scaffold for antigen production
in tobacco chloroplasts. Front. Plant Sci. 6, 1170 (2015).
19.

Berguer, P. M., Mundi√±ano, J., Piazzon, I. & Goldbaum, F. A. A polymeric bacterial

protein activates dendritic cells via TLR4. J. Immunol. 176, 2366‚Äì2372 (2006).
20.

Berguer, P. M. et al. A polymeric protein induces specific cytotoxicity in a TLR4

dependent manner in the absence of adjuvants. PloS One 7, e45705 (2012).
21.

Craig, S. J., Foong, F. C. & Nordon, R. Engineered proteins containing the cohesin

and dockerin domains from Clostridium thermocellum provides a reversible, high affinity
interaction for biotechnology applications. J. Biotechnol. 121, 165‚Äì173 (2006).
22.

Craig, P. et al. Multiple display of a protein domain on a bacterial polymeric scaffold.

Proteins Struct. Funct. Bioinforma. 61, 1089‚Äì1100 (2005).
23.

Pishesha, N., Ingram, J. R. & Ploegh, H. L. Sortase A: A model for transpeptidation

34

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

and its biological applications. Annu. Rev. Cell Dev. Biol. 34, 163‚Äì188 (2018).
24.

Tang, S., Xuan, B., Ye, X., Huang, Z. & Qian, Z. A modular vaccine development

platform based on sortase-mediated site-specific tagging of antigens onto virus-like
particles. Sci. Rep. 6, 1‚Äì9 (2016).
25.

Arbeitman, C. R. et al. Structural and functional comparison of SARS-CoV-2-spike

receptor binding domain produced in Pichia pastoris and mammalian cells. Sci. Rep. 10,
(2020).
26.

Huang, X. et al. Kinetic mechanism of Staphylococcus aureus sortase SrtA.

Biochemistry 42, 11307‚Äì11315 (2003).
27.

Tandon, R. et al. Effective screening of SARS-CoV-2 neutralizing antibodies in

patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein.
Sci. Rep. 10, 1‚Äì7 (2020).
28.

Zylberman, V. et al. High order quaternary arrangement confers increased structural

stability to Brucella sp. lumazine synthase. J. Biol. Chem. 279, 8093‚Äì8101 (2004).
29.

Sosa, S. et al. Asymmetric bifunctional protein nanoparticles through redesign of

self-assembly. Nanoscale Adv. 1, 1833‚Äì1846 (2019).
30.

Okba, N. M. et al. Particulate multivalent presentation of the receptor binding domain

induces protective immune responses against MERS-CoV. Emerg. Microbes Infect. 9,
1080‚Äì1091 (2020).
31.

Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through

engineering a bacterial adhesin. Proc. Natl. Acad. Sci. 109, E690‚ÄìE697 (2012).
32.

Zhang, B. et al. A platform incorporating trimeric antigens into self-assembling

nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher
neutralizing responses than spike alone. Sci. Rep. 10, 1‚Äì13 (2020).

35

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

33.

Powell, A. E. et al. A single immunization with spike-functionalized ferritin vaccines

elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent. Sci.
(2021).
34.

Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly

neutralizing H1N1 antibodies. Nature 499, 102‚Äì106 (2013).
35.

Jangra, S. et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but

does not abolish neutralizing activity of human convalescent and post-vaccination sera.
medRxiv (2021).
36.

Andreano, E. et al. SARS-CoV-2 escape in vitro from a highly neutralizing

COVID-19 convalescent plasma. bioRxiv (2020).
37.

Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike

receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44‚Äì57
(2021).
38.

Gu, H. et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.

Science 369, 1603‚Äì1607 (2020).
39.

Chan, K. K. et al. Engineering human ACE2 to optimize binding to the spike protein

of SARS coronavirus 2. Science 369, 1261‚Äì1265 (2020).
40.

Van Den Berg, S., L√∂fdahl, P.-√Ö., H√§rd, T. & Berglund, H. Improved solubility of

TEV protease by directed evolution. J. Biotechnol. 121, 291‚Äì298 (2006).
41.

Popp, M. W., Antos, J. M. & Ploegh, H. L. Site‚ÄêSpecific Protein Labeling via

Sortase‚ÄêMediated Transpeptidation. Curr. Protoc. Protein Sci. 56, 15‚Äì3 (2009).
42.

Batista, P. de O. M. D. et al. Methods of endotoxin removal from biological

preparations: a review. (2007).
43.

Capcha, J. M. C. et al. Generation of SARS-CoV-2 Spike pseudotyped virus for viral

36

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.25.441271; this version posted April 26, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY 4.0 International license.

entry and neutralization assays: A 1-week protocol. Front. Cardiovasc. Med. 7, (2020).
44.

Ferrara, F. & Temperton, N. Pseudotype neutralization assays: from laboratory bench

to data analysis. Methods Protoc. 1, 8 (2018).

37

